Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Quest Diagnostics (DGX) significantly surpassed Q2 2025 expectations, reporting $2.76 billion in revenue (up 15.2% Y/Y) and $2.62 EPS, prompting an upward revision to its full-year 2025 guidance. However, the company highlighted potential future challenges from ongoing tariffs and a projected $100 million financial impact if the Protecting Access to Medicare Act (PAMA) is not deferred. This strong performance and outlook, despite the noted headwinds, led to a 6.19% surge in DGX shares and an reiterated Outperform rating from William Blair.

Analysis

Quest Diagnostics (DGX) reported a robust second quarter for 2025, exceeding analyst estimates on both revenue and earnings. Revenue grew 15.2% year-over-year to $2.76 billion, surpassing the $2.73 billion consensus, while adjusted EPS of $2.62 also beat expectations. This performance was primarily fueled by a significant 16.3% increase in requisition volume, although organic volume growth was a more modest 2.1%, highlighting the impact of acquisitions. Despite a minor 0.4% decrease in revenue per requisition, the company improved its adjusted operating margin to 16.9% through productivity gains. Buoyed by these results, management raised its full-year 2025 guidance for revenue and EPS, with the new midpoints now above consensus. However, this positive outlook is tempered by two significant headwinds: an ongoing, unquantified negative impact from tariffs and a potential $100 million financial hit if the Protecting Access to Medicare Act (PAMA) is not deferred. The stock, which rose 6.19% on the news, now trades at 16 times forward earnings, a slight premium to its 10-year average of 15, which analysts suggest is justified by its consistent growth profile.

Key Decisions for Investors

• The strong beat-and-raise quarter supports a constructive outlook, but investors must closely monitor legislative news regarding the Protecting Access to Medicare Act (PAMA), as its non-deferral represents a quantified $100 million risk to earnings.
• Investors should assess the sustainability of growth, noting the significant contribution from acquisitions (16.3% total volume growth vs. 2.1% organic) when evaluating the stock's valuation premium at 16 times forward earnings.
• Consider the ongoing, albeit unquantified, negative impact from tariffs as a potential drag on margins for the remainder of 2025, which could offset some of the operational efficiency gains.